"Eli Lilly Stock Soars Amidst Market Downturn"

Eli Lilly's stock (NYSE: LLY) is experiencing a notable rise, outperforming the overall market slump due to investor optimism about its weight-loss drug Zepbound, which is expected to compete strongly with Novo Nordisk's products. Despite a high forward price-to-earnings ratio, analysts suggest that Eli Lilly's growth potential, driven by Zepbound and other factors, makes the stock a worthwhile investment. However, it's important to note that The Motley Fool's Stock Advisor service did not include Eli Lilly in its top 10 recommended stocks for investors.